How to Build a Medtech Investor Narrative That Converts
To build a medtech investor narrative, founders need five components: a market creation claim, traction evidence that signals repeatability, commercial infrastructure proof, an acquirer thesis with named strategic rationale, and a timing argument grounded in category urgency.
Most pre-traction founders arrive at LSI East with the clinical story, not the investor story. That gap is what stalls rounds.
How Market Engineering Helps MedTech Startups Raise Capital
Why Clinical Proof Alone Does Not Close a Medtech Investment Round
The meeting always ends the same way.
You present your study. You show the outcomes. You walk through the mechanism of action.
The investor nods. And then they say: "This is really interesting. Come back when you have more traction."
You leave thinking you need more data. You don't. You need a different document.
The clinical story explains mechanism of action, study design, and surgical outcomes. An investor story explains market opportunity, commercial infrastructure, and exit pathway. These are architecturally different documents built for different audiences solving different problems.
I covered this on an episode about how market engineering helps medtech startups raise capital. An investor described exactly what they're looking for when a founder walks in the door:
Don't tell us about the TAM. We're not interested. $10 billion. That's great. Who's going to buy this? How many people have you talked to already? What's the commercial traction look like for this thing once you hit the regulatory milestones?
That's the investor narrative gap in one paragraph. Most founders come in with a $10 billion TAM and leave confused about why the round didn't close.
The Five Components of a Medtech Investor Narrative
1. Market creation claim
This answers a deceptively hard question: why didn't this category exist before you? The answer cannot be "the technology didn't exist." That's an engineering story. The investor story explains the structural gap in adoption, the behavior change required, and why the timing is right to define the category now.
2. Traction evidence
I covered this on an episode about market engineering and fundraising. Here's how traction was defined there:
Traction, believe it or not, it's not revenue or product launch or clinical milestones. The way you want to think about traction is that it's repeatable, measurable demand. Revenue can be episodic. You can have a launch and get lucky, but one or two or three deals even does not mean you're going to have a repeatability, it doesn't mean you have a predictability, or even scalability.
Founders confuse traction with activity. An investor looking at your Series A doesn't want to know you closed three accounts. They want to know those three accounts taught you a replicable commercial motion.
3. Commercial infrastructure proof
This is not a sales deck. It's evidence of market engineering.
Which physicians have you activated as KOLs? Which IDNs are in conversation? What evidence exists that pull-driven demand is forming, not just push-driven sales activity?
The medtech commercialization strategy framework we use at MarketCraft distinguishes between the two. Most founders present push evidence and wonder why investors aren't convinced.
4. Acquirer thesis
Most medtech exits come down to a single buyer, no competitive tension, no negotiating leverage. I covered this dynamic on an episode about seven lessons from $17 billion in medtech exits:
No competitive tension. You're not negotiating. You're literally just accepting. You have no leverage.
Your investor narrative must name the two or three strategics most likely to acquire you, explain why they need what you've built rather than build it themselves, and describe the category dynamics that would push them to pay a premium for category ownership rather than feature competition.
5. Timing argument
This is not a market size argument. It's a category urgency argument. Why does the window for owning this category close in the next 18 to 24 months? What clinical, regulatory, or competitive event makes now the decision point rather than three years from now?
How Ray Cohen and Greg Lucier Built Their Narratives Before the Exits
The Ray Cohen playbook at Axonics is the clearest example of how a medtech investor narrative gets built in practice.
Cohen didn't enter the OAB market as a competitor to Medtronic's InterStim. He entered as the founder of a new category: rechargeable sacral neuromodulation. The narrative wasn't "we're better." The narrative was "we're the company that created the version of this therapy patients would choose."
That market creation claim shaped everything downstream. The traction evidence wasn't just installations. It was the reorder pattern, the physician NPS, the patient-reported outcomes that signaled pull-driven demand forming.
And the acquirer thesis was specific: a strategic who needed a category position in neuromodulation and couldn't build Axonics' lead from scratch without years of clinical trust.
The result was a $3.7B exit at a category premium, not a feature discount. See the full Axonics acquisition breakdown.
Greg Lucier ran the same architecture at NuVasive. He built spine into a category NuVasive owned, not a segment it competed in.
By the time strategic conversations happened, NuVasive wasn't being evaluated on product features. It was being evaluated on what it would cost a competitor to replicate the commercial infrastructure NuVasive had spent years building. That's the difference the acquirer thesis creates.
I've seen this pattern repeatedly. On an episode about hardball strategy and winning in medtech, the same dynamic appeared:
The deal didn't close in the deal room. The market was shaped years before. A pre-revenue medical robotics company essentially walks into their first conference. No one seems to know them except all three of the strategic acquirers that they're interested in all end up in the booth at the same time uninvited.
That's not luck. That's a market narrative doing its job before anyone sat down to negotiate.
What This Means for Medtech Founders
In my experience working with medtech founders, the investor narrative gap shows up the same way almost every time. The clinical team produced a great story. The commercial team packaged it for physicians. And nobody built the third document: the one for investors that connects clinical proof to commercial conviction.
LSI East is coming up this fall. If you're planning to walk into that conference and raise capital, your clinical data presentation is not the document that will close the round. The investor narrative is.
The five things investors need to see are a market creation claim that explains why you own the category, traction evidence that signals repeatability not just activity, and commercial infrastructure that proves pull-driven demand is forming.
Beyond that, they need an acquirer thesis with named strategics and real rationale, and a timing argument that creates urgency without panic.
The medtech exit playbook covers the downstream mechanics. But the upstream work of building narrative architecture before the exit conversation begins is where most founders underinvest. And it's where the biggest valuation gap opens.
Frequently Asked Questions
What Is a Medtech Investor Narrative?
A medtech investor narrative is the commercial-facing document that translates clinical validation into investor conviction. It explains market opportunity, commercial traction, and exit pathway in the terms investors evaluate.
Unlike a clinical presentation, it answers what a strategic acquirer would pay for and why the category window is open now rather than in three years.
How Is a Medtech Investor Narrative Different From a Clinical Data Presentation?
A clinical data presentation explains mechanism of action, study design, and surgical outcomes to physicians and regulators. A medtech investor narrative explains market creation, traction evidence, commercial infrastructure, and acquirer thesis to investors.
The same clinical results can be packaged both ways, but each document serves a different decision and a different audience.
What Should a Medtech Investor Narrative Include for Series A?
For Series A, the narrative must include a market creation claim explaining why this category didn't exist before you, traction evidence that signals repeatable demand rather than episodic sales, commercial infrastructure proof of pull-driven adoption, a named acquirer thesis with specific strategic rationale, and a timing argument grounded in category urgency rather than general market size.
How Do You Build a Medtech Investor Narrative When You Don't Have Commercial Traction Yet?
Build the narrative on leading indicators, not lagging ones. Named physician champions, IDN conversations in progress, documented KOL activation, and replicable commercial motion signals all count as traction evidence before revenue scales.
Frame traction as what's repeatable, not just what's happened. Investors fund the architecture that makes the next quarter look more like the current quarter, not a single lucky quarter.
Listen to the Full Conversations
The episodes that shaped this post are available on The State of MedTech.
- How Market Engineering Helps MedTech Startups Raise Capital
- 7 Lessons from $17B in Medtech Exits That Every Founder Must Know
- Why Barbarians Always Beat Bureaucrats: Hardball Strategy and the Psychology of Winning
Subscribe wherever you listen to podcasts.
About the Author
Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.
He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.